Evolus’ (EOLS) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Monday morning,Benzinga reports. The brokerage currently has a $18.00 price target on the stock.

Several other brokerages have also recently weighed in on EOLS. Needham & Company LLC reaffirmed a “hold” rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. HC Wainwright dropped their target price on shares of Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Evolus from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $21.25.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $7.35 on Monday. The stock has a market cap of $475.40 million, a price-to-earnings ratio of -7.50 and a beta of 1.07. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. Evolus has a 12 month low of $5.71 and a 12 month high of $17.82. The stock’s 50 day moving average price is $8.15 and its 200 day moving average price is $10.05.

Insider Activity at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of Evolus stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the transaction, the chief marketing officer owned 89,949 shares in the company, valued at approximately $675,516.99. The trade was a 5.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brady Stewart acquired 30,000 shares of Evolus stock in a transaction that occurred on Friday, August 15th. The stock was acquired at an average cost of $6.82 per share, with a total value of $204,600.00. Following the completion of the purchase, the director owned 88,629 shares in the company, valued at approximately $604,449.78. This represents a 51.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 133,627 shares of company stock worth $1,325,764. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Evolus

Several institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC raised its holdings in shares of Evolus by 830.2% during the second quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock worth $974,000 after acquiring an additional 94,423 shares in the last quarter. Caxton Associates LLP purchased a new position in Evolus in the second quarter valued at about $148,000. Tower Research Capital LLC TRC increased its position in Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after purchasing an additional 5,691 shares during the last quarter. Soleus Capital Management L.P. raised its stake in shares of Evolus by 96.4% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after purchasing an additional 1,039,842 shares in the last quarter. Finally, Man Group plc lifted its holdings in shares of Evolus by 23.5% during the 2nd quarter. Man Group plc now owns 125,749 shares of the company’s stock valued at $1,158,000 after buying an additional 23,922 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.